This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day
for 4 weeks by subjects with atopic dermatitis (eczema).

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Lebanon

Arcutis Clinical Site 55

ARQ-151 Active

ARQ-151 Vehicle

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy
(RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy
and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued
following radiation therapy.

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

Dartmouth-Hitchcock Medical Center

Optune®

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood
cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of
non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in
adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or
R/R follicular lymphoma (FL). Adverse events will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R
FL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab.
Participants will receive escalating doses of epcoritamab, until full dose is achieved.
Approximately 80 adult participants with R/R DLBCL and R/R FL will be enrolled in the study
in approximately 40 in the United States of America.
Participants will receive escalating doses of subcutaneous epcoritamab, until full dose is
achieved, in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at an approved
institution (hospital or clinic). The effect of the treatment will be frequently checked by
medical assessments, blood tests, questionnaires and side effects.

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Dartmouth-Hitchcock Medical Center /ID# 245003

Epcoritamab

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Grade 1-3a When Administered in the Outpatient Setting

The main purpose of this study is to measure the effect, safety and how well the body absorbs
lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe
atopic dermatitis (AD).

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Dartmouth Hitchcock Medical Center

Lebrikizumab

Placebo

Topical corticosteroid

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Migraine is a common neurological disorder typically characterized by attacks of throbbing,
moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light
and sound. Migraine is extremely common and disabling in children. The purpose of this study
is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in
children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and
adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will
include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants
aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis
to determine dose selection for the main study. In the main study, after dose selection,
children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant
or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo.
Adolescents aged 12-17 years will be randomized to receive either low or high dose of
Ubrogepant or placebo with a 1 in 3 chance of placebo assignment.
For qualifying migraine attacks, participants will receive oral tablets of the double-blind
study intervention. There will be an option to take a second dose of double-blind study
intervention (identical to initial dose), or rescue medication, 2 to 24 hours after the
initial dose, for headache of moderate/severe intensity. Around 1059 participants will be
enrolled in the study in approximately 120 sites in the United States. The study duration
will be up to 6 months.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Nashua

Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 230312

Ubrogepant

Placebo-Matching Ubrogepant

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

This post-marketing study is designed to compare the safety of baricitinib versus tumor
necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when
given to participants with rheumatoid arthritis (RA).

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Baricitinib

TNF Inhibitor

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd)
in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or
metastatic non-small cell lung cancer (NSCLC).

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Datopotamab Deruxtecan

Pembrolizumab

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

This feasibility pilot study is designed to learn whether patients and their care partners
(e.g., family members) are willing and able to complete two study visits at Dartmouth College
while receiving cancer care at Dartmouth-Hitchcock Medical Center.

The Science of the Art of Palliative Care

Specialty Palliative Care

The Science of the Art of Palliative Care Pilot

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination
with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide
versus standard therapy alone for the treatment of poorly differentiated extrapulmonary
(originated outside the lung) neuroendocrine cancer that may have spread from where it first
started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has
spread from where it first started (primary site) to other places in the body (metastatic).
The other aim of this trial is to compare using atezolizumab just at the beginning of
treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin
are in a class of medications known as platinum-containing compounds that work by killing,
stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known
as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA
repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug
(cisplatin or carboplatin) and etoposide may work better in treating patients with poorly
differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a
platinum drug (cisplatin or carboplatin) and etoposide alone.

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Atezolizumab

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Etoposide

Magnetic Resonance Imaging

Patient Observation

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC #783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or
metastatic conventional chondrosarcoma patients.

Study of INBRX-109 in Conventional Chondrosarcoma

Norris Cotton Cancer Center

INBRX-109

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

New Hampshire